SyncroScan™ is basically an emission spectrometer that utilizes proprietary synchronous UV- Vis scanning, excitation-emission/fluorescence and Principle Component Analysis (PCA) software. SyncroScan™ is able to instantaneously identify multiple pathogenic types in unknown samples by matching them with the company’s spectroscopic “fingerprint” library. SyncroScan’s proprietary software incorporates Machine Learning and AI to expand speed, accuracy and security of data acquisition, analysis and storage.
The Company is raising capital to complete the development of its SyncroScan™ system, and launch it in the marketplace. If you are interested in investing in, or, partnering with SparkSigma please contact us.
(President and Founder) has more than 40 years of industrial management experience. As President of Crane Technical Materials, he grew a start-up business to a globally recognized company, that sold to Neenah (NYSE:NP). Dennis held BOD Positions for companies in Asia and Europe and serves on Texas A&M’s College of Science External Advisory and Development Committee.
Co-inventor on six (6) patent families with applications and patents totaling 43. Holds a B.S. Chemistry, Texas A&M University (1977) and a M.S. Industrial Administration, Union College (1993).
(Vice President and Co-Founder) brings to SparkSigma more than 35 years of experience in medical product development, operational scale up, clinical trials, sales, marketing, and management at all levels.
Over the course of his career, Mr. Hoon’s expertise has been critical in the clinical development, regulatory approval process, manufacturing scale-up, and sales and marketing of various medical products and devices. To date, Mr. Hoon has brought over twenty medical devices to market. Mr. Hoon also holds a process patent as well as several patent applications. Mr. Hoon is the co-author of several clinical and scientific publications.
(Interim CFO) Greg brings over 25 years of private equity investment and business development experience, primarily in medtech and pharma. He has served on more than 20 boards of directors both private and publicly traded companies and has been involved with 7 IPOs and 5 mergers.
He holds a B.S. Engineering, Princeton University and a M.S. Engineering and M.S. Management, Massachusetts Institute of Technology. Greg currently sits on the Columbia University Department of Ophthalmology Board of Advisors.